Valitor to present on its drug candidate with twice-yearly dosing for wet amd at the american academy of ophthalmology's eyecelerator conference and the association for research in vision and ophthalmology (arvo) annual meeting

- proprietary multivalent polymer (mvp) platform enables the engineering of potent, long-acting therapies - proprietary multivalent polymer (mvp) platform enables the engineering of potent, long-acting therapies
AMD Ratings Summary
AMD Quant Ranking